Trial
NCT00746382
A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
Fougera Pharmaceuticals Inc.
Condition
Dermatitis
Intervention
Roflumilast cream
Why stopped
Study withdrawn due to business decisions. No subjects were treated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-12-01